An Open Label Trial of TMS Therapy for Bipolar Depression

NCT ID: NCT02640950

Last Updated: 2022-06-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 31 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-12-31
• Study Completion Date: 2020-07-31

Brief Summary

Transcranial Magnetic Stimulation (TMS) is an increasingly accepted neurostimulation- based treatment for major depressive disorder. While there is a growing anecdotal database supporting its use in bipolar depression the investigators propose to collect open label efficacy and safety data in a small population of patients with clinically verified bipolar disorder.

Detailed Description

The investigators propose to screen patients with bipolar depression I or II, who are already on acceptable mood stabilization. They may or may not be on antidepressants at the time of screening but subjects on antidepressants would be taken off them before completing the screening phase. Those patients who have a depression of at least moderate severity without significant symptoms of activation or mania will be started on a course of open label TMS treatment of up to 35 sessions. Safety and efficacy assessments will be done weekly. Patients will complete a course of treatment when they meet remission criteria (MADRS score < 10) or at the end of 30 treatments, whichever comes first. Patient who are still judged to be improving between treatment 25 and treatment 30 will be eligible to complete up to five addition treatments as the discretion of each site's principal investigator. Patients who meet response criteria (MADRS score decreases by at least 50%) will complete the full course of 30 to 35 TMS sessions. Patients will be withdrawn for safety concerns, particularly the onset of activation suggestive of mania or a mixed state.

Patients who meet response or remission criteria will be followed monthly for up to six months to evaluate the durability of response. They will be on standard mood stabilizing medications and psychotherapy per their clinician's discretion.

Conditions

Bipolar Depression

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Open-Label TMS

Active Transcranial Magnetic Stimulation

Group Type: EXPERIMENTAL

NeuroStar TMS

Intervention Type: DEVICE

Transcranial Magnetic Stimulation

Interventions

NeuroStar TMS

Transcranial Magnetic Stimulation

Intervention Type: DEVICE

Other Intervention Names

Transcranial Magnetic Stimulation

Eligibility Criteria

Inclusion Criteria

1. Must be at least 18 years old.

2. Must meet DSM-5 criteria for bipolar (either I or II) depression by clinical interview and M.I.N.I. The duration of the current depressive episode must be at least 4 weeks and no longer than 3 years in length.

3. Should have a MADRS score of at least 20 at screening, an YMRS score of less than 12 and a CGI score of at least 4.

4. Must have signed the informed consent document and have a level of understanding sufficient to provide informed consent and to communicate with the investigator and site personnel.

5. Must be on a mood stabilizer acceptable to the study physician which is consistent with their diagnosis. The mood stabilizer must be at a stable dose for at least four days before starting TMS treatment.

6. If female of childbearing potential, patients must

1. have a negative urine pregnancy test at screening, and

2. not be nursing or planning a pregnancy, and

3. be on a medically acceptable method of birth control acceptable to the principal investigator.

Choices of contraception that meet the study requirements are

• Intrauterine device
• Hormonal contraception (estrogen-containing birth control pills, Vaginal ring, patch, injections or implants)
• Latex condom with spermicide
• Diaphragm with spermicide
• Cervical cap with spermicide

Females of childbearing potential who are abstinent can enroll in the study.

Exclusion Criteria

1. May not be directly affiliated with Sheppard Pratt Clinical Research Programs or be immediate family of Research Programs personnel.

2. Must not have another primary Axis I diagnosis.

3. The subject must not have stopped an antidepressant less than two weeks before starting TMS treatment or unable to discontinue antidepressant therapy.

4. Should have no previous history of psychosis or substance dependence or abuse within the six months prior to Screening

5. Presence of an Axis II disorder felt by the investigator to potentially interfere with study compliance would exclude a potential participant.

6. Should not have prior intolerance of TMS or significant lack of response to adequate trials of TMS.

7. Should not have a lifetime history of lack of response to ECT or VNS.

8. Should not have any medical condition likely to interfere with safe study participation.

9. Women of child-bearing potential who are not using a medically accepted means of contraception when engaging in sexual intercourse are excluded, as well as women who are pregnant or breast-feeding.

10. Positive urine screen for any substance of abuse will exclude a patient, with the exception of benzodiazepines. A satisfactory explanation in the opinion of the investigator along with a negative repeat screen prior to Visit 2 is possibly acceptable.

11. Current suicide risk, as evidenced:

1. It is the judgment of the investigator that the patient may be at risk for suicide

2. The patient has rated a "yes" to question 4 or question 5 on the Screening C-SSRS

3. The patient has attempted suicide within the past 12 months prior to Screening.

12. History of head injury, epilepsy or seizure disorder, non-removable metallic implants or objects in or around the head.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Mayo Clinic

OTHER

Sponsor Role: collaborator

Sheppard Pratt Health System

OTHER

Sponsor Role: lead

Responsible Party

Scott T. Aaronson, M.D

Director, Clinical Research Programs

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Scott T Aaronson, MD

Role: PRINCIPAL_INVESTIGATOR

Sheppard Pratt Health System

Locations

Sheppard Pratt Health System

Baltimore, Maryland, United States

Department of Psychiatry and Psychology, Mayo Clinic

Rochester, Minnesota, United States

Countries

United States

References

Aaronson ST, Goldwaser EL, Croarkin PE, Geske JR, LeMahieu A, Sklar JH, Kung S. A Pilot Study of High-Frequency Transcranial Magnetic Stimulation for Bipolar Depression. J Clin Psychiatry. 2024 May 20;85(2):23m15056. doi: 10.4088/JCP.23m15056.

Reference Type: DERIVED

PMID: 38780536 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

794736-5

Identifier Type: -

Identifier Source: org_study_id